Showing results (1621-1630 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|August 28, 2020
Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II studyAbdullah K Altwairgi, Waleed A Alghareeb, Fouad H AlNajjar, et al.
Investigational New Drugs|September 30, 2020
Discovery of oxyepiberberine as a novel tubulin polymerization inhibitor and an anti-colon cancer agent against LS-1034 cellsHanbing Ning, Wenquan Lu, Qiaoyu Jia, et al.
Investigational New Drugs|October 2, 2020
Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapyZhiqiang Wu, Wenbo Guo, Song Chen, et al.
Investigational New Drugs|January 10, 2019
A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumorsToshihiko Doi, Takeshi Aramaki, Hirofumi Yasui, et al.
Investigational New Drugs|November 30, 2018
A mediator of phosphorylated Smad2/3, evodiamine, in the reversion of TAF-induced EMT in normal colonic epithelial cellsWanbin Yang, Xiuli Gong, Xiulian Wang, et al.
Investigational New Drugs|June 1, 1988
In vivo and in vitro investigations on biological effects of aromatic bis-(2-chloroethyl)amino-bisphosphonic acids, new agents proposed for chemotherapy of bone tumors: cytostatic activity in rat osteosarcoma; toxicity and genotoxicity in liver and bone marrow; mutagenicity in S. typhimuriumB L Pool, M Berger, J R Schlehofer, et al.
Investigational New Drugs|December 6, 2019
Combination of a novel microtubule inhibitor MBRI-001 and gemcitabine synergistically induces cell apoptosis by increasing DNA damage in pancreatic cancer cell linesYuqian Liu, Ruochen Zang, Feifei Li, et al.
Investigational New Drugs|February 21, 2018
Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cellsJade K Pollock, Lisa M Greene, Seema M Nathwani, et al.
Investigational New Drugs|February 18, 2018
A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumorsHideki Ueno, Shunsuke Kondo, Shusuke Yoshikawa, et al.
Investigational New Drugs|February 22, 2018
The concomitant use of lapatinib and paracetamol - the risk of interactionAgnieszka Karbownik, Edyta Szałek, Katarzyna Sobańska, et al.
Pageof 372